About 1 100 reports

pathology.

  • Pathology
  • Therapy
  • World
  • Supply
  • Medestea

## (Cyclooxygenase-## or COX-## or Prostaglandin- Endoperoxide Synthase ## or EC ##. ##. ##. ##) Prostaglandin G/ H Synthase ## (Cyclooxygenase-## or COX-## or Prostaglandin- Endoperoxide Synthase ## or EC ##. ##. ##. ##) ## ## ## ## ## ## ## ## ## ALK Tyrosine Kinase

  • Pathology
  • United States
  • Auspex Pharmaceuticals, Inc.
  • Cephalon, Inc.
  • ChemGenex Pharmaceuticals Limited

Lung damage pathology is caused by both influenza virus infection and expansion, and the body' s immune response to fight the infection.

  • Influenza
  • Pathology
  • Vaccine
  • United States
  • Product Initiative

Lung damage pathology is caused by both influenza virus infection and expansion, and the body' s immune response to fight the infection.

  • Influenza
  • Pathology
  • Vaccine
  • United States
  • Product Initiative

Additionally, two patients underwent surgery following aldoxorubicin treatment, and the pathology analysis of the removed tissue showed no viable tumor.

  • Pathology
  • Therapy
  • United States
  • Product Initiative
  • Merck & Co., Inc.

It develops therapeutics for nervous system pathologies involving human endogenous retroviruses.

  • Neurological Disorder
  • Pathology
  • United States
  • World
  • Product Initiative

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Pathology
  • United States
  • World
  • Product Initiative
  • Kadmon Corporation, LLC

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Pathology
  • United States
  • World
  • Product Initiative
  • Kadmon Corporation, LLC

The molecules developed by Companies in Phase I, Preclinical and Discovery stages are ##, ## and ## respectively.

  • Neurological Disorder
  • Pathology
  • United States
  • World
  • AndroScience Corporation, Inc

This vector was confirmed to provide GAA expression and activity in target tissues, improved muscle pathology and a favorable immunogenicity profile.

  • Pathology
  • United States
  • World
  • Product Initiative
  • Amicus Therapeutics

The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ## and ## respectively.

  • Neurological Disorder
  • Pathology
  • United States
  • World
  • AndroScience Corporation, Inc

The molecules developed by companies in Phase II, Phase ##, Preclinical and Discovery stages are ##, ##, ## and ## respectively.

  • Pathology
  • United States
  • World
  • Product Initiative
  • Virobay Inc.

The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Neurology
  • Pathology
  • Therapy
  • Type 2 Diabetes
  • Regeneron Pharmaceuticals, Inc.

The molecules developed by companies in Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical and Discovery stages are ##, ##, ##, ##, ## and ## respectively.

  • Pathology
  • Vaccine
  • United States
  • World
  • Product Initiative

Similarly, the universities portfolio in Preclinical and Discovery stages comprises ## and ## molecules, respectively.

  • Genetic Engineering
  • Pathology
  • United States
  • World
  • Product Initiative

In part ##, patients will be randomized on a ##:##:## basis to receive one of two active doses (## mg or ## mg) of PRX##/ RG## or placebo via intravenous infusion once every ## weeks.

  • Pathology
  • United States
  • World
  • Company
  • Product Initiative

The drug candidate acts by dual mechanism, it targets heparanase enzyme, VEGF, FGF-##, FGF-##.

  • Cancer
  • Oncology
  • Pathology
  • Pharmaceutical
  • Therapy

Down Syndrome - Overview Down Syndrome - Therapeutics Development NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR DOWN SYNDROME, H## 2018 PIPELINE OVERVIEW NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR DOWN SYNDROME, H## 2018 Phase I ## ## Preclinical ## ## Discovery ## ## Unknown ## ## Total ## ## NUMBER OF PROD

  • Dementia
  • Pathology
  • United States
  • World
  • Product Initiative

The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are ##, ##, ## and ## respectively.

  • Pathology
  • United States
  • World
  • Product Initiative
  • Acceleron Pharma, Inc.

Patients were randomized to one of five treatment groups in a ##:##:##:##:## fashion: fasinumab ##mg, ##mg, ##mg, ##mg, or placebo, all delivered subcutaneously every ## weeks through week ##, with the primary efficacy measured at week ##.

  • Chronic Pain
  • Pathology
  • World
  • Product Initiative
  • Pfizer Inc.

The molecules developed by companies in Phase II, Preclinical and Discovery stages are ##, ## and ## respectively.

  • Clinical Trial
  • Pathology
  • Therapy
  • World
  • Product Initiative

The molecules developed by Companies in Phase II and Preclinical stages are ## and ## respectively.

  • Pathology
  • United States
  • World
  • Product Initiative
  • AbbVie Inc.

The molecules developed by Companies in Phase II and Preclinical stages are ## and ## respectively.

  • Neurological Disorder
  • Pathology
  • World
  • Product Initiative
  • Pfizer Inc.

At the end of the experimental period (## days) mice were imaged using T##-weighted MRI for brainstem pathology; brain and spinal cord tissue were then collected for histological analysis.

  • Pathology
  • United States
  • World
  • Product Initiative
  • Biogen Idec Inc.

Namodenoson improved liver pathology in a NAFLD/ diabetes animal model of NASH.

  • Cardiovascular Drug
  • Hepatitis
  • Pathology
  • Therapy
  • Can-Fite BioPharma Ltd.

Anakinra blocks the biologic activity of interleukin-## by competitively inhibiting interleukin-## binding to the interleukin-## type I receptor (IL ##RI), which is expressed in a wide variety of tissues and organs.

  • Cardiovascular Disease
  • Pathology
  • World
  • Product Initiative
  • Evotec AG

Sanyal, MD, lead study author and Professor of Medicine, Physiology and Molecular Pathology, School of Medicine at Virginia Commonwealth University.

  • Pathology
  • Therapy
  • World
  • Product Initiative
  • Gilead Sciences, Inc.

It offers preventative treatment on the diagnosis of amyloid plaque pathology before dementia.

  • Pathology
  • United States
  • World
  • Product Initiative
  • NeuroGenetic Pharmaceuticals, Inc.

Patients were randomized to one of five treatment groups in a ##:##:##:##:## fashion: fasinumab ##mg, ##mg, ##mg, ##mg, or placebo, all delivered subcutaneously every ## weeks through week ##, with the primary efficacy measured at week ##.

  • Chronic Pain
  • Monoclonal Antibody
  • Pathology
  • Pharmaceutical
  • Therapy

James Talmadge, Professor, Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE and will involve animal viral challenge studies and an analysis of the immune responses thereto.

  • Infectious Disease
  • Pathology
  • United States
  • World
  • Product Initiative